Thomas Schirrmann

Thomas Schirrmann Email and Phone Number

CEO @ YUMAB GmbH
Brunswick, NDS, DE
Thomas Schirrmann's Location
Brunswick, Lower Saxony, Germany, Germany
Thomas Schirrmann's Contact Details

Thomas Schirrmann work email

Thomas Schirrmann personal email

n/a
About Thomas Schirrmann

Development of fully human, therapeutic antibodies from target to lead in less than 12 months!

Thomas Schirrmann's Current Company Details
YUMAB GmbH

Yumab Gmbh

View
CEO
Brunswick, NDS, DE
Website:
yumab.com
Employees:
24
Thomas Schirrmann Work Experience Details
  • Yumab Gmbh
    Ceo
    Yumab Gmbh
    Brunswick, Nds, De
  • Corat Therapeutics
    Chief Operating Officer
    Corat Therapeutics Sep 2020 - Present
    Operations, investor relations, second generation compounds COR-201
  • Yumab Gmbh
    Ceo
    Yumab Gmbh 2013 - Present
    Braunschweig, Niedersachsen, De
    Management, Strategy, Partnering
  • Corat Therapeutics Gmbh
    Ceo
    Corat Therapeutics Gmbh May 2020 - Sep 2020
    Development of COVID-19 antibody therapeutics; fast-track program; first financing round; definition of lead compound COR-101; initiation of CMC activities
  • Tu Braunschweig
    Research Group Leader
    Tu Braunschweig 2005 - 2013
    Braunschweig, Niedersachsen, De
    Research with focus on human antibody discovery and development, recombinant protein production, novel antibody formats, bispecific antibodies and therapeutic antibody fusion proteins, >70 publications, Coordination of the German NGFN2 project "Antibody Factory", Subprojects in EU FP7 "Affinity proteome" and "Affinomics"
  • Charité
    Promotion
    Charité 2001 - 2004
    Berlin, De
    Research in immunology, tumor vaccination and targeting of immune cells with gene modified immune cells (CAR-NK)
  • Max Delbrück Center
    Scientist
    Max Delbrück Center 1997 - 2001
    Berlin, Berlin, De
    Research in tumor immunology, gene therapy, cellular immunotherapy, Natural Killer (NK) cells, dendritic cells (DCs)

Thomas Schirrmann Skills

Phage Display Monoclonal Human Antibodies Antibody Engineering Protein Expression Immunology Molecular Biology Mammalian Cell Culture Protein Production Bispecific Antibodies Therapeutic Antibody Fusion Proteins Protein Engineering Protein Assays Affinity Maturation Tumor Immunology Bacterial Culture

Thomas Schirrmann Education Details

  • Humboldt-Universität Zu Berlin
    Humboldt-Universität Zu Berlin
    Immunologie
  • Humboldt-Universität Zu Berlin
    Humboldt-Universität Zu Berlin
    Biochemie

Frequently Asked Questions about Thomas Schirrmann

What company does Thomas Schirrmann work for?

Thomas Schirrmann works for Yumab Gmbh

What is Thomas Schirrmann's role at the current company?

Thomas Schirrmann's current role is CEO.

What is Thomas Schirrmann's email address?

Thomas Schirrmann's email address is th****@****mab.com

What schools did Thomas Schirrmann attend?

Thomas Schirrmann attended Humboldt-Universität Zu Berlin, Humboldt-Universität Zu Berlin.

What skills is Thomas Schirrmann known for?

Thomas Schirrmann has skills like Phage Display, Monoclonal Human Antibodies, Antibody Engineering, Protein Expression, Immunology, Molecular Biology, Mammalian Cell Culture, Protein Production, Bispecific Antibodies, Therapeutic Antibody Fusion Proteins, Protein Engineering, Protein Assays.

Who are Thomas Schirrmann's colleagues?

Thomas Schirrmann's colleagues are Annika Schaperjahn, Jenny Bischoff, Melanie Philippi, Niklas Deja, Ansgar Eickhoff, Nina Hoffmann, Ulrike Beier.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.